Calidi Biotherapeutics Receives Pre-IND Regulatory Feedback From FDA Providing Alignment, Clarity On IND-Enabling Preclinical Plans And Clinical Strategy For CLD-401 Prior To Advancing Drug Candidate Into Phase 1 Clinical Studies

Loading news article.

Calidi Biotherapeutics Receives Pre-IND Regulatory Feedback From FDA Providing Alignment, Clarity On IND-Enabling Preclinical Plans And Clinical Strategy For CLD-401 Prior To Advancing Drug Candidate Into Phase 1 Clinical Studies | WAPE

Calidi Biotherapeutics Receives Pre-IND Regulatory Feedback From FDA Providing Alignment, Clarity On IND-Enabling Preclinical Plans And Clinical Strategy For CLD-401 Prior To Advancing Drug Candidate Into Phase 1 Clinical Studies

Article summary

Related companies

Comments —